Sitagliptin (JANUVIA) Post Marketing Surveillance Protocol.

Trial Profile

Sitagliptin (JANUVIA) Post Marketing Surveillance Protocol.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Jun 2012 Actual patient number 2974 added as reported by ClinicalTrials.gov.
    • 19 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top